Follow the people · Insider
Faraz Ali
Faraz Ali files insider transactions with the SEC as a chief executive officer of Tenaya Therapeutics (TNYA). We hold 3 disclosed purchases and sales filed since 2 March 2016, 1 of them in the last 90 days.
- Files forTNYA
- Disclosed buys and sells3 in all, 1 in the last 90 days
- Last disclosure17 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 15 February 2022 — 17 August 2026Chief Executive Officer · Tenaya Therapeutics (TNYA)40 Form 4 lines · source: SEC Form 4
- Filed 2 March 2016 — 4 January 2017Chief Business Officer · Regenxbio (RGNX)2 Form 4 lines · source: SEC Form 4
Everything they disclosed
42 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 5,837 shares of Tenaya TherapeuticsSEC Form 417 August 2026Common Stock · traded 17 August 2026 · filed 17 August 2026
- ▼ sold on the open market 3,969 shares of Tenaya TherapeuticsSEC Form 417 August 2026Common Stock · traded 17 August 2026 · filed 17 August 2026
- ▼ sold on the open market 5,020 shares of Tenaya TherapeuticsSEC Form 417 August 2026Common Stock · traded 17 August 2026 · filed 17 August 2026
- ▼ sold on the open market 7,406 shares of Tenaya TherapeuticsSEC Form 417 August 2026Common Stock · traded 17 August 2026 · filed 17 August 2026
- ▼ sold on the open market 3,390 shares of Tenaya TherapeuticsSEC Form 419 May 2026Common Stock · traded 18 May 2026 · filed 19 May 2026
- ▼ sold on the open market 5,851 shares of Tenaya TherapeuticsSEC Form 417 February 2026Common Stock · traded 17 February 2026 · filed 17 February 2026
- ▼ sold on the open market 3,979 shares of Tenaya TherapeuticsSEC Form 417 February 2026Common Stock · traded 17 February 2026 · filed 17 February 2026
- ▼ sold on the open market 5,032 shares of Tenaya TherapeuticsSEC Form 417 February 2026Common Stock · traded 17 February 2026 · filed 17 February 2026
- ▼ sold on the open market 5,851 shares of Tenaya TherapeuticsSEC Form 417 February 2026Common Stock · traded 17 February 2026 · filed 17 February 2026
- ▼ sold on the open market 3,979 shares of Tenaya TherapeuticsSEC Form 417 February 2026Common Stock · traded 17 February 2026 · filed 17 February 2026
- ▼ sold on the open market 5,032 shares of Tenaya TherapeuticsSEC Form 417 February 2026Common Stock · traded 17 February 2026 · filed 17 February 2026
- was granted 158,600 shares of Tenaya TherapeuticsSEC Form 45 February 2026Common Stock · traded 3 February 2026 · filed 5 February 2026
- was granted 952,250 shares of Tenaya Therapeutics (a derivative holding)SEC Form 45 February 2026Stock Option (Right to buy) · traded 3 February 2026 · filed 5 February 2026
- was granted 952,250 shares of Tenaya Therapeutics (a derivative holding)SEC Form 45 February 2026Stock Option (Right to buy) · traded 3 February 2026 · filed 5 February 2026
- was granted 158,600 shares of Tenaya TherapeuticsSEC Form 45 February 2026Common Stock · traded 3 February 2026 · filed 5 February 2026
- ▼ sold on the open market 3,126 shares of Tenaya TherapeuticsSEC Form 417 November 2025Common Stock · traded 17 November 2025 · filed 17 November 2025
- ▼ sold on the open market 5,720 shares of Tenaya TherapeuticsSEC Form 418 August 2025Common Stock · traded 18 August 2025 · filed 18 August 2025
- ▼ sold on the open market 3,893 shares of Tenaya TherapeuticsSEC Form 418 August 2025Common Stock · traded 18 August 2025 · filed 18 August 2025
- ▼ sold on the open market 4,920 shares of Tenaya TherapeuticsSEC Form 418 August 2025Common Stock · traded 18 August 2025 · filed 18 August 2025
- ▼ sold on the open market 3,189 shares of Tenaya TherapeuticsSEC Form 416 May 2025Common Stock · traded 16 May 2025 · filed 16 May 2025
- ▼ sold on the open market 5,794 shares of Tenaya TherapeuticsSEC Form 410 March 2025Common Stock · traded 10 March 2025 · filed 10 March 2025
- ▼ sold on the open market 3,947 shares of Tenaya TherapeuticsSEC Form 410 March 2025Common Stock · traded 10 March 2025 · filed 10 March 2025
- was granted 650,000 shares of Tenaya Therapeutics (a derivative holding)SEC Form 47 February 2025Stock Option (Right to buy) · traded 6 February 2025 · filed 7 February 2025
- returned to the issuer 353,271 shares of Tenaya Therapeutics (a derivative holding)SEC Form 47 February 2025Stock Option (Right to Buy) · traded 6 February 2025 · filed 7 February 2025
- was granted 353,271 shares of Tenaya Therapeutics (a derivative holding)SEC Form 47 February 2025Stock Option (Right to Buy) · traded 6 February 2025 · filed 7 February 2025
- returned to the issuer 161,214 shares of Tenaya Therapeutics (a derivative holding)SEC Form 47 February 2025Stock Option (Right to Buy) · traded 6 February 2025 · filed 7 February 2025
- was granted 161,214 shares of Tenaya Therapeutics (a derivative holding)SEC Form 47 February 2025Stock Option (Right to Buy) · traded 6 February 2025 · filed 7 February 2025
- returned to the issuer 401,390 shares of Tenaya Therapeutics (a derivative holding)SEC Form 47 February 2025Stock Option (Right to Buy) · traded 6 February 2025 · filed 7 February 2025
- was granted 401,390 shares of Tenaya Therapeutics (a derivative holding)SEC Form 47 February 2025Stock Option (Right to Buy) · traded 6 February 2025 · filed 7 February 2025
- was granted 107,500 shares of Tenaya TherapeuticsSEC Form 47 February 2025Common Stock · traded 6 February 2025 · filed 7 February 2025
- was granted 34,424 shares of Tenaya TherapeuticsSEC Form 47 February 2025Common Stock · traded 6 February 2025 · filed 7 February 2025
- ▼ sold on the open market 5,802 shares of Tenaya TherapeuticsSEC Form 416 August 2024Common Stock · traded 16 August 2024 · filed 16 August 2024
- ▼ sold on the open market 3,946 shares of Tenaya TherapeuticsSEC Form 416 August 2024Common Stock · traded 16 August 2024 · filed 16 August 2024
- was granted 505,000 shares of Tenaya Therapeutics (a derivative holding)SEC Form 427 February 2024Stock Option (Right to buy) · traded 23 February 2024 · filed 27 February 2024
- was granted 85,000 shares of Tenaya TherapeuticsSEC Form 427 February 2024Common Stock · traded 23 February 2024 · filed 27 February 2024
- ▼ sold on the open market 6,358 shares of Tenaya TherapeuticsSEC Form 416 February 2024Common Stock · traded 16 February 2024 · filed 16 February 2024
- ▼ sold on the open market 5,563 shares of Tenaya TherapeuticsSEC Form 418 August 2023Common Stock · traded 16 August 2023 · filed 18 August 2023
- was granted 675,000 shares of Tenaya Therapeutics (a derivative holding)SEC Form 417 February 2023Stock Option (Right to buy) · traded 15 February 2023 · filed 17 February 2023
- was granted 125,000 shares of Tenaya TherapeuticsSEC Form 417 February 2023Common Stock · traded 15 February 2023 · filed 17 February 2023
- was granted 401,390 shares of Tenaya Therapeutics (a derivative holding)SEC Form 417 February 2022Stock Option (Right to buy) · traded 15 February 2022 · filed 17 February 2022
- was granted 25,200 shares of Regenxbio (a derivative holding)SEC Form 46 January 2017Stock Option (Right to Buy) · traded 4 January 2017 · filed 6 January 2017
- was granted 200,000 shares of Regenxbio (a derivative holding)SEC Form 42 March 2016Stock Option (Right to Buy) · traded 2 March 2016 · filed 2 March 2016
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.